Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.66
    -0.41 (-13.36%)

    Market Cap: $10.13M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Intensity Therapeutics, Inc. Common stock (INTS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Intensity Therapeutics, Inc. Common stock (INTS) has a market cap of $10.13M and an enterprise value of $1.64M. Revenue fell 208.33% over the last 12 months from the 12 months before. It holds $8.49M more cash than debt, 83.81% of its market cap.

    Total Valuation

    Enterprise value is 83.81% below the market cap, as cash exceeds debt.

    Market Cap$10.13M
    Enterprise Value$1.64M
    Latest price (Nov 17, 2026)$2.66

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 20.34% in the quarter ended Sep 30, 2026.

    Shares Outstanding3.26M
    Shares Change (QoQ)+20.34%

    Price Statistics

    The stock is down 75.71% over 52 weeks and trades 23.56% below its 50-day average.

    Beta (1Y)1.36
    52-Week Change-75.71%
    1-Month Change-19.15%
    3-Month Change-36.67%
    6-Month Change-42.05%
    Total Return (1Y)-75.71%
    Total Return (3Y CAGR)-62.99%
    Return vs SPY (1Y)-86.81%
    Max Drawdown (1Y)-81.97%
    Max Drawdown (3Y)-98.92%
    Sharpe Ratio (1Y)-1.72
    Correlation with SPY (1Y)0.23
    50-Day Average$3.48
    200-Day Average$4.83
    52-Week Range$2.80 to $15.00
    RSI (14 Days)32.0
    Average Volume (20 Days)14.68K

    Price chart

    Financial Position

    Current assets cover 3.68x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.68x
    Quick Ratio3.68x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -157.29% and return on assets is -117.00% over the last 12 months.

    Return on Equity (ROE)-157.29%
    Return on Assets (ROA)-117.00%

    Scores

    INTS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was -$26.00K over the last 12 months.

    Revenue-$26.00K
    Revenue Growth (YoY)-208.33%
    Gross Profit-$7.00K
    Operating Income-$12.37M
    Pretax Income-$12.04M
    Net Income-$12.04M
    Reported EPS (TTM)-$4.37

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.34% of the $10.29M in total assets.

    Cash and Equivalents$8.49M
    Total Debt$0
    Net Cash$8.49M
    Net Cash Per Share$2.61
    Working Capital$6.92M
    Shareholder Equity$7.65M
    Book Value Per Share$2.35
    Total Assets$10.29M
    Total Liabilities$2.63M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$9.07M
    FCF Per Share-$2.78
    Depreciation and Amortization$27.00K
    Share Repurchases$684.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    INTS does not pay a dividend.

    Buyback Yield-121.12%
    Shareholder Yield-121.12%

    Stock Splits

    The last split was a 1-for-25 reverse split on Feb 19, 2026.

    Last Split DateFeb 19, 2026
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About INTS

    What is INTS's market cap?

    Intensity Therapeutics, Inc. Common stock has a market cap of $10.13M. Its enterprise value, which adds debt and subtracts cash, is $1.64M.

    How many shares of INTS are outstanding?

    Intensity Therapeutics, Inc. Common stock has 3.26M shares outstanding.

    Does INTS pay a dividend?

    No. Intensity Therapeutics, Inc. Common stock does not pay a dividend.

    How much debt does INTS have?

    Intensity Therapeutics, Inc. Common stock has $0 of total debt and $8.49M of cash and equivalents, a net cash position of $8.49M.